ReviewIncidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy
Introduction
The incidence of hepatitis B virus (HBV) infection varies widely between countries, with the estimated life time risk of infection ranging from 0.4% in the UK to over 90% in East Asia (Ramsay et al., 1998, Kane et al., 1993). A likely explanation for this marked difference is that a higher incidence is linked to a lower average age at infection, which has a much higher probability of development of HBV carriage, and therefore of onward transmissions (Edmunds et al., 1996a, Medley et al., 2001).
Although the incidence of infection in England and Wales is amongst the lowest in the world, its potential to cause chronic infection with serious sequelae such as cirrhosis and cancer of the liver means that control of HBV infection is still a public health priority.
Safe and effective vaccines to prevent HBV infection have been available since 1982, and the World Health Organization (WHO) recommended that all countries should have implemented universal immunisation programmes by 1997 (WHO, 1992). However, the current HBV control programme in the UK is based upon selective immunisation of those at highest risk of infection and universal antenatal screening and immunisation of babies born to infected mothers (NHS, 1998, Salisbury and Begg, 1996). The UK strategy is based on the observation that overall incidence of HBV is low, that the risk of infection is distributed heterogeneously in the population (Mortimer and Miller, 1997), and that it is determined mainly by country of birth, ethnicity and adult risk behaviours such as injecting drug use (Soldan et al., 2000, Aweis et al., 2001, Department of Health, 2000).
There is a continuing need to examine the effectiveness of the UK’s HBV vaccination strategy. This is done by analysing current incidence and patterns of transmission. The main source of data for this is the laboratory surveillance of acute HBV infection in England and Wales, complemented by prevalence surveys among groups at different risk of infection. The surveys allow quantification of the burden of infection at a population level, including the many chronic infections acquired prior to immigration into the UK. These latter infections are not preventable by any UK programme, and they limit the potential impact of vaccination on the overall burden of HBV infection.
We have analysed recent routine surveillance data on acute HBV infection in England and Wales, estimated the number of infections imported through immigration, and discuss implications for the control of HBV through immunisation.
Section snippets
Patients and samples
Laboratories in England and Wales routinely report acute HBV infections and associated risk factors to the Health Protection Agency-Communicable Disease Surveillance Centre (HPA-CDSC). A case of acute HBV infection is normally defined by positive serology for HBsAg and anti-HBc IgM, or seroconversion to anti-HBc detected during epidemiological investigation in a person with or without a compatible illness. Cases reported between 1 January 1995 and 31 December 2000 were included in the analyses.
Incidence of acute HBV infection and demographics
Between 1995 and 2000, on average 673 cases of laboratory confirmed acute HBV infection were reported to the HPA-CDSC each year, with a peak of 840 cases in 1998 (Fig. 1). The average incidence of laboratory reports was 1.3 per 100,000 per year, with an incidence rate of 1.6 per 100,000 per year among those aged 15 years or older.
The number of reports represents an estimated total of 3,780 infections per year, resulting in an estimated 269 new chronic infections per year. From this, the true
Discussion
Our analyses of laboratory surveillance of acute HBV infection in England and Wales between 1995 and 2000 suggest that the incidence of HBV has remained at a low level, though with a modest increase in 1998. This increase was mainly due to an increase in the number of cases reported to have resulted from injecting drug use, and a single outbreak linked to autohaemotherapy (Webster et al., 2000).
The cumulative risk of infection at adult age based on our current incidence estimate is similar to
Acknowledgements
We are grateful to all laboratories reporting acute HBV infections, to Usha Gungabissoon and Nigel Gay (HPA-CDSC) and to Rhian Tyler (International Migration Supervisor, ONS).
References (31)
- et al.
Vaccination against hepatitis B virus in highly endemic areas: waning vaccine-induced immunity and the need for booster doses
Trans. R. Soc. Trop. Med. Hyg.
(1996) - et al.
Control of hepatitis B in the United Kingdom
Vaccine
(1998) - et al.
The prevalence of hepatitis B infection in adults with no recognized increased risk of infection
J. Infect.
(2000) - et al.
Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy
Lancet
(2000) - et al.
Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpool
Commun. Dis. Public. Health
(2001) - et al.
Acute hepatitis B infection in England and Wales: 1985–1996
Epidemiol. Infect.
(1999) - et al.
The prevalence of hepatitis B and C in an antenatal population of various ethnic origins
Epidemiol. Infect.
(1994) - Bradford Health Authority & City of Bradford Metropolitan District Council. Nam Pehchan....
- CDC, Achievements in public health: hepatitis B vaccination—United States, 1982–2002. Morb Mortal Wkly Rep...
- CDC, Health and Human Services Agency SD. Hepatitis B vaccination in high-risk sites....
The influence of age on the development of the hepatitis B carrier state
Proc. R. Soc. Lond. B Biol. Sci.
The transmission dynamics and control of hepatitis B virus in The Gambia
Stat. Med.
Developed countries could pay for hepatitis B vaccination in developing countries
BMJ
Cited by (139)
Hepatitis B: A cross-sectional survey of knowledge, attitudes and practices amongst backpackers in Thailand
2017, Travel Medicine and Infectious DiseaseCitation Excerpt :There was no significant difference in risk taking behaviours between backpackers of European and non-European origins. Non-immune individuals who partake in high-risk activities whilst visiting endemic countries are at risk of developing hepatitis B; in the UK twelve percent of acute HBV cases in the UK reported overseas travel during the incubation period [28]. Contracting HBV whilst travelling has consequences not just for the individual but also for their close contacts on return home and the healthcare system of their country of origin.
Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994
2016, Clinical Microbiology and InfectionOptimal Control of Hepatitis B in a sub-Saharan African rural area
2023, Applied Mathematics